Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegcantratinib - Sienna Biopharmaceuticals

Drug Profile

Pegcantratinib - Sienna Biopharmaceuticals

Alternative Names: CT 301/P; CT 327; K-252a-PEG2K; Pegylated K252A; SNA-120

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cephalon
  • Developer Creabilis SA; Sienna Biopharmaceuticals
  • Class Antipsoriatics; Carbazoles; Indole alkaloids; Skin disorder therapies; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis; Pruritus
  • Discontinued Neuropathic pain

Most Recent Events

  • 14 May 2019 Sienna Biopharmaceuticals completes End-of-Phase II meeting with the US FDA
  • 14 May 2019 Updated efficacy results from a phase IIb trial in Psoriasis released by Sienna Biopharmaceuticals
  • 14 Mar 2019 Sienna Biopharmaceuticals schedules an End-of-Phase 2 (EOP2) meeting with the US FDA in April 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top